By: W. Langbein
Who would have guessed that taking two diabetes drugs combined in one tablet would offer greater glucose-lowering benefits than taking the same two drugs in separate but still co-administered tablets?
A glyburide/metformin tablet, marketed in the United States as Glucovance, delivered a significantly greater reduction in A1C than a prior regimen of glyburide co-administered with metformin.
According to a study from Bristol-Myers Squibb and the Ochsner Clinic Foundation in New Orleans, the effect was especially significant when a patient’s baseline A1C level was 8%.
The therapy was tested in 950 patients—471 of whom received glyburide co-administered with metformin. The average A1C decrease for the combination tablet group was 2.02%, compared with a decrease of 1.49% for glyburide co-administered with metformin, despite the fact that the patients receiving the combination tablet received lower doses of the medications.
The study data were obtained from retrospective pharmacy claims data and corresponding laboratory results from a usual-care setting.
Diabetes, Obesity and Metabolism, November 2003